PRTA - Prothena Corporation plc

Prothena to Participate in Jefferies 2023 Healthcare Conference

DUBLIN, June 02, 2023--Prothena today announced that it will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 1:00 PM ET.

• 
  CyberArk to Present at Upcoming Investor Conferences

  Business Wire
• 
  Schrödinger to Present at Goldman Sachs 44th Annual Global Healthcare Conference

  Business Wire

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

DUBLIN, May 16, 2023--Prothena announced today the appointment of Dr. Billy Dunn, the founding Director of the Office of Neuroscience, CDER, to its Board of Directors.

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

DUBLIN, May 04, 2023--Prothena today reported financial results for the first quarter of 2023 and provided business highlights.

Prothena to Report First Quarter 2023 Financial Results on May 4

DUBLIN, April 27, 2023--Prothena today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023.

Prothena to Participate in 2023 Bank of America Healthcare Conference

DUBLIN, April 24, 2023--Prothena today announced that members of its management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference.

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

DEERFIELD, Ill. & DUBLIN, April 13, 2023--Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease. As part of the collaboration, Walgreens will leverage its national footprint, portfolio of industry-leading healthca

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

DUBLIN, March 31, 2023--Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Prothena to Participate in Stifel 2023 Virtual CNS Days

DUBLIN, Ireland, March 21, 2023--Prothena announced today that members of its senior management team will participate in a fireside chat at Stifel 2023 Virtual CNS Days on March 28 .

Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting

DUBLIN, March 14, 2023--Prothena announced broad participation at AD/PD 2023 highlighting leadership in advancing treatments for Alzheimer’s and Parkinson’s disease

Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

DUBLIN, February 23, 2023--Prothena Corporation plc today reported financial results for the 4th quarter and full year 2022.

Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

DUBLIN, February 16, 2023--Prothena Corporation plc announced that it will report its fourth quarter and full year 2022 financial results on February 23, 2023.

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, February 03, 2023--Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease

DUBLIN, January 31, 2023--Prothena announced positive topline Phase 1 SAD study results for PRX005, an investigational tau antibody for the treatment of Alzheimer’s disease.

Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares

DUBLIN, December 15, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In add

Prothena Announces Proposed Public Offering of Ordinary Shares

DUBLIN, December 13, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the n

Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

DUBLIN, December 12, 2022--Prothena presented data from phase 3 VITAL study observing a statistically significant survival benefit in patients with Mayo Stage IV AL amyloidosis.

Prothena Reports Third Quarter 2022 Financial Results and Business Highlights

DUBLIN, November 03, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2022 and provided a business update.

Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting

DUBLIN, November 03, 2022--Prothena Corporation plc today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at ASH 2022.